Early access to doxecitine and doxribtimine for TK2d
Part of Genetic & congenital, Immune system & allergy clinical trials.
This program provides early access to two experimental medicines (doxecitine and doxribtimine) for people with TK2d, a rare inherited condition that causes muscle weakness and other serious symptoms. The goal is to offer treatment when no other clinical trial is available, and it may help slow disease progression.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of TK2d, a rare genetic condition that affects energy production in cells.
- Your symptoms must put you at risk of serious disability or early death (for one part of the program).
- You must be willing to take the study drugs (doxecitine and doxribtimine) and share your medical information with the sponsor.
- You cannot join if you are already in another clinical trial for TK2d.
- You should not have significant liver problems, kidney failure needing dialysis, or be unable to take oral medication.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two experimental drugs, Doxecitin and Doxribthymine, for adults with a rare genetic condition called TK2 deficiency that causes muscle weakness and breathing problems. The goal is to see if these drugs can slow or stop the disease.
This Phase 2 trial tests a treatment made from deoxynucleosides to help people with mitochondrial depletion disorder caused by certain gene changes. If you match the genetic diagnosis, the study may see whether the treatment improves symptoms or disease markers.
This trial tests a new medicine called EDK060 for people with Charcot-Marie-Tooth disease type 1A (CMT1A). The study will check if the drug is safe and how the body processes it, with the goal of finding better treatments for this condition.
This trial tests a nucleoside therapy (dC/dT) for people with telomere biology disorders, which cause premature aging and problems like low blood counts, lung or liver issues. The goal is to see if the treatment can help manage these symptoms.
This early-stage trial tests JR-446, a new treatment for MPS IIIB, a rare genetic disorder that affects the brain and body. The treatment is delivered directly into the fluid around the spinal cord and aims to slow or improve symptoms in young children.
This trial tests an experimental drug called TGRX-678 for people with a specific, more advanced stage of chronic myeloid leukemia (CML) called 'accelerated phase.' It’s for patients whose cancer has stopped responding to or who couldn't tolerate earlier targeted therapies (tyrosine kinase inhibitors).
Hear when a new Thymine Kinase 2 Deficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.